Business Description
Provectus Biopharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US74373P1084
Description
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (HXs). Its lead HX molecule is named rose bengal sodium. The Company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of its current clinical development programs and the preclinical formulations of its current drug discovery programs.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | -5.24 | |||||
| Debt-to-Equity | -0.4 | |||||
| Debt-to-EBITDA | -1.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 16.4 | |||||
| 3-Year EPS without NRI Growth Rate | 20.6 | |||||
| 3-Year FCF Growth Rate | 15.7 | |||||
| 3-Year Book Growth Rate | 38.1 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.83 | |||||
| 9-Day RSI | 56 | |||||
| 14-Day RSI | 55.17 | |||||
| 6-1 Month Momentum % | 21.21 | |||||
| 12-1 Month Momentum % | 19.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.15 | |||||
| Quick Ratio | 0.15 | |||||
| Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.7 | |||||
| Shareholder Yield % | -0.86 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -180.65 | |||||
| ROIC % | -70.74 | |||||
| ROC (Joel Greenblatt) % | -2594.42 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -29.28 | |||||
| EV-to-EBITDA | -29.37 | |||||
| EV-to-FCF | -32.85 | |||||
| Earnings Yield (Greenblatt) % | -3.42 | |||||
| FCF Yield % | -3.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PVCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Provectus Biopharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.006 | ||
| Beta | 1.21 | ||
| Volatility % | 108.85 | ||
| 14-Day RSI | 55.17 | ||
| 14-Day ATR ($) | 0.013465 | ||
| 20-Day SMA ($) | 0.190871 | ||
| 12-1 Month Momentum % | 19.59 | ||
| 52-Week Range ($) | 0.056 - 0.2245 | ||
| Shares Outstanding (Mil) | 419.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Provectus Biopharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Provectus Biopharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Provectus Biopharmaceuticals Inc Frequently Asked Questions
What is Provectus Biopharmaceuticals Inc(PVCT)'s stock price today?
The current price of PVCT is $0.19. The 52 week high of PVCT is $0.22 and 52 week low is $0.06.
When is next earnings date of Provectus Biopharmaceuticals Inc(PVCT)?
The next earnings date of Provectus Biopharmaceuticals Inc(PVCT) is 2024-08-14 Est..
Does Provectus Biopharmaceuticals Inc(PVCT) pay dividends? If so, how much?
Provectus Biopharmaceuticals Inc(PVCT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers